stratified by ulcer healing status. Work productivity loss was captured weekly by the Work Productivity and Activity Impairment (WPAI) Questionnaire [1] specific for VLU. RESULTS: The mean direct medical cost of treating VLU during the study period was estimated to be $1772 per patient for US payers, $1294 for US providers, and £1502 in the UK. The largest direct medical cost component was for professional services, or labor (approximately 70%), followed by dressing, compression bandages, and medications. Patients who had at least one ulcer not healed at the end of study had higher mean costs compared to those patients who had all ulcers healed ($2250 vs. $1012 from the US payer perspective, $1625 vs. $862 from the US provider perspective, and £1770 vs. £965 from the UK NHS perspective). Over the 12-week study duration, more reductions in work productivity loss and activity impairment were found in the healed group vs. the non-healed group. CONCLUSIONS: VLU imposes significant medical costs and work productivity losses. Since the cost of professional services is the main cost driver in the treatment of VLU, new technologies that reduce the professional labor time could significantly reduce the economic burden of venous leg ulcer. 
METHODS:
Hospitalization events and duration of hospital stay were recorded for each patient in the DUET trials. Differences in hospitalizations and total days hospitalized at 48 weeks were compared between ETR + BR and placebo + BR in the pooled DUET population. Daily hospital costs were collected from the Belgian IMS Hospital Disease database, a longitudinal patient-level retrospective database. A sample of 277 HIV patients with 397 hospitalizations in Belgium were extracted. An average cost per day was calculated in 2007 Euros, which included INAMI (health system cost) and patient contribution costs for medications, procedures, and rooming charges. These costs were applied to the total days observed in the DUET trials to estimate overall hospital costs. RESULTS: A total of 1203 patients were included from the DUET trials: 599 vs. 604 in the ETR vs. placebo groups. Baseline characteristics and average follow-up were comparable between arms. The number (%) of patients hospitalized was 105 (18%) for ETR + BR vs. 139 (23%) for placebo + BR, respectively (p = 0.0006). Total hospital days observed during the 48 week follow-up period were 1702 for ETR + BR vs. 2747 for placebo + BR. The average cost per patient day was estimated to be €556.39. Over the population, total hospital costs were estimated to be €946,676 for ETR + BR vs. €1,528,403 for placebo + BR. CONCLUSIONS: At Week 48, ETR + BR provided a statistically significant reduction the number of patients hospitalized vs. placebo + BR. The reductions in the number of hospitalizations and time spent in the hospital represent clinical benefit to the patients and significant savings in hospital-related costs to the health care system. 
